Get the Stockscreener App
2.32
4.98%
0.11
Pre-market:
2.30
-0.02
-0.86%
Kyverna Therapeutics Inc stock is traded at $2.32, with a volume of 351.82K.
It is up +4.98% in the last 24 hours and up +12.62% over the past month.
Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product, KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.
See More
Previous Close:
$2.21
Open:
$2.21
24h Volume:
351.82K
Relative Volume:
1.31
Market Cap:
$86.87M
Revenue:
-
Net Income/Loss:
$-110.66M
P/E Ratio:
-0.7493
EPS:
-3.0963
Net Cash Flow:
$-97.76M
1W Performance:
+15.42%
1M Performance:
+12.62%
6M Performance:
-54.15%
1Y Performance:
-84.14%
1-Day Range:
$2.16
$2.32
1-Week Range:
$1.95
$2.32
52-Week Range:
$1.78
$17.55
Kyverna Therapeutics Inc Stock (KYTX) Company Profile
Name
Kyverna Therapeutics Inc
Sector
Industry
Phone
(510) 626-8331
Address
5980 HORTON STREET, EMERYVILLE
Compare KYTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KYTX
Kyverna Therapeutics Inc
|
2.32 | 86.87M | 0 | -110.66M | -97.76M | -3.0963 |
|
VRTX
Vertex Pharmaceuticals Inc
|
432.00 | 115.57B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
574.16 | 60.30B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
542.47 | 37.56B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
266.86 | 35.18B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
224.73 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
Kyverna Therapeutics Inc Stock (KYTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-10-24 | Initiated | UBS | Buy |
| Oct-09-24 | Initiated | Rodman & Renshaw | Buy |
| Jul-03-24 | Initiated | H.C. Wainwright | Neutral |
| Mar-04-24 | Initiated | JP Morgan | Overweight |
| Mar-04-24 | Initiated | Leerink Partners | Outperform |
| Mar-04-24 | Initiated | Morgan Stanley | Overweight |
| Mar-04-24 | Initiated | Wells Fargo | Overweight |
View All
Kyverna Therapeutics Inc Stock (KYTX) Latest News
Kyverna Therapeutics to attend the 2024 American Academy of Neurology (AAN) Annual Meeting in Denver, CO, With Data on KYV-101 in the Treatment of Patients with Neurological Autoimmune Diseases - Seeking Alpha
Kyverna Therapeutics Provides Business Update And Reports First Quarter 2025 Financial Results - marketscreener.com
Kyverna's Autoimmune Pipeline Hits Major Milestones: SPS Trial Full, MG Phase 3 Gets FDA Green Light - Stock Titan
KYTX Stockholders Have Opportunity to Lead Kyverna Therapeutics, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today! - ACCESS Newswire
Kyverna Therapeutics (KYTX) to Release Quarterly Earnings on Tuesday - MarketBeat
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Kyverna Therapeutics - ACCESS Newswire
Kyverna Therapeutics, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky Before February 7, 2025 to Discuss Your Rights – KYTX - ACCESS Newswire
Kyverna Therapeutics Inc expected to post a loss of $1.11 a shareEarnings Preview - TradingView
Class Action Filed Against Kyverna Therapeutics, Inc. (KYTX)February 7, 2025 Deadline to Join – Contact Levi & Korsinsky - ACCESS Newswire
KYVERNA THERAPEUTICS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Ky - ACCESS Newswire
Shareholders that lost money on Kyverna Therapeutics, Inc.(KYTX) should contact Levi & Korsinsky about pending Class ActionKYTX - ACCESS Newswire
Shareholders that lost money on Kyverna Therapeutics, Inc.(KYTX) Urged to Join Class Action – Contact Levi & Korsinsky to Learn More - ACCESS Newswire
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Kyverna Therapeutics, Inc. (KYTX) Shareholders - ACCESS Newswire
Shareholders of Kyverna Therapeutics, Inc. Should Contact Levi & Korsinsky Before February 7, 2025 to Discuss Your RightsKYTX - ACCESS Newswire
Press Release Distribution & PR Platform - ACCESS Newswire
Brokerages Set Kyverna Therapeutics, Inc. (NASDAQ:KYTX) PT at $18.33 - MarketBeat
Kyverna Therapeutics, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before February 7, 2025 to Discuss Your RightsKYTX - ACCESS Newswire
KYTX Stock Price and Chart — NASDAQ:KYTX - TradingView
Gilead Sciences Inc. Purchases New Position in Kyverna Therapeutics, Inc. (NASDAQ:KYTX) - MarketBeat
JPMorgan Chase & Co. Sells 220,915 Shares of Kyverna Therapeutics, Inc. (NASDAQ:KYTX) - MarketBeat
Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Shares Sold by Franklin Resources Inc. - MarketBeat
Notice to Long-Term Shareholders of Kyverna Therapeutics, - GlobeNewswire
Notice to Long-Term Shareholders of Kyverna Therapeutics, Inc. (NASDAQ: KYTX); Methode - Bluefield Daily Telegraph
Notice to Long-Term Shareholders of Kyverna Therapeutics, Inc. (NASDAQ: KYTX); Methode Electronics, Inc. (NYSE: MEI); ModivCare, Inc. (NASDAQ: MODV); and Monolithic Power Systems, Inc. (NASDAQ: MPWR)Grabar Law Office Is Investigating Claims - TradingView
Investigation announced for Long-Term Investors in shares of Kyverna Therapeutics, Inc. (NASDAQ: KYTX) - openPR.com
Kyverna Therapeutics Inc Stock (KYTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Kyverna Therapeutics Inc Stock (KYTX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Jones Ryan Alexander | Chief Financial Officer |
May 28 '24 |
Option Exercise |
0.73 |
18,016 |
13,152 |
43,950 |
3.01%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):